This review assessed the use of beta-blockers in patients with intermittent claudication (IC). The authors concluded there was no evidence to suggest that clinicians should be cautious in prescribing beta-blockers to patients with IC. Limitations in the conduct of the review and methods of analysis mean that the results of the meta-analyses are unreliable. However, the authors' overall conclusions are suitably cautious.
generalisability of the results. Statistical heterogeneity was assessed and the studies were combined in a meta-analysis. However, studies assessing two or more beta-blocker treatments were included more than once in each analysis. This means that the results of the meta-analyses are unreliable. In addition, the included studies were very small (23 patients or fewer) and were of short-term treatment (longest lasted 10 weeks); these factors should also be considered when interpreting the results. The results of the individual studies presented in this review seem reliable, but the results of the meta-analyses should be treated with caution. The authors' cautious conclusions about the lack of evidence in this area appear appropriate, but this review was not sufficiently robust to make any claims about precautions in drug packaging, particularly as none of the included studies were conducted in Japan and the review did not assess adverse events.
